Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies

Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively characterized in vitro and in vivo to support the f...

Celý popis

Podrobná bibliografie

Vydáno v:	Frontiers in pharmacology Ročník 15; s. 1392209
Hlavní autoři:	Jiang, Shuwen, Li, Xiangkun, Xue, Weifang, Xia, Sumei, Wang, Jian, Sai, Yang, Dai, Guangxiu, Su, Weiguo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media S.A 2024
Témata:	drug–drug interaction hematological malignancies in vitro in vivo extrapolation pharmacokinetics PI3Kδ tissue distribution hematological malignancies pharmacokinetics PI3Kδ drug–drug interaction in vitro in vivo extrapolation tissue distribution
ISSN:	1663-9812, 1663-9812
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!